Filing Flows

Filing Flows › Pacific Biosciences of California (PACB) › Next earnings date

Pacific Biosciences of California (PACB) earnings: beat the estimate

Pacific Biosciences of California (PACB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.11 against −$0.13 (+16.1%). Revenue was $40.6M for Q3 2026, +6% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+16.1% vs estimate
Beat rate80%

The last report

Pacific Biosciences of California reported revenue of $40.6M for the third quarter 2026 (+6% Y/Y), net loss $37.8M: Product revenue $34.0M, Service and other revenue $6.6M. How it makes money → · Every quarter →

Pacific Biosciences of California: EPS against the estimate, last 5 reportsPacific Biosciences of California: EPS against the estimate, last 5 reportsEstimateReported−$0.14−$0.12Nov 25−$0.13−$0.12Feb 26−$0.13−$0.12May 26−$0.13−$0.14Aug 26−$0.13−$0.11Nov 26
Latest (Nov 26): Estimate −$0.13, Reported −$0.11.

Pacific Biosciences of California's latest quarter

Pacific Biosciences of California, Q3 2026: revenue $40.6M (+6% year over year), operating margin -91.2%, net loss $37.8M, operating cash flow −$37.6M. The chart follows the revenue to costs, profit and cash.

Questions

Did Pacific Biosciences of California beat earnings?

Pacific Biosciences of California (PACB) reported on Nov 4, 2026 and beat the EPS estimate: −$0.11 against −$0.13 (+16.1%).

When does PACB report earnings?

The next date is not set yet.

Does Pacific Biosciences of California usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.